Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Sunda Energy PLC (AIM:SNDA, FRA:GHA0) has raised £5.25 million to fund completion of its New Zealand acquisition. It's also launching a retail offer for a further £525,000. Meridian Mining Plc (LSE:MNO, TSX:MNO, OTCQX:MRRDF) has delivered a net present value of $2.09 billion for its Cabaçal project in Brazil. The CEO says the economics could make it the next major near-term gold-copper mine. Quantum Helium Ltd (AIM:QHE) is targeting Q4 2026 for a larger fracture stimulation programme at Sagebrush-1 in Colorado. It's also taking a 9% stake in Herencia Resources. Light Science Technologies Holdi
Iofina PLC (AIM:IOF, OTC:IOFNF) jumped over 4% in early trading after boosting output at its IO#11 plant with a new brine source. It said the extra supply should lift crystalline iodine production there by 50%. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) says final preliminary drilling results back up the scale of its Discovery Zone at Mushima North in Zambia. It's now heading towards a maiden resource estimate this year. Quantum Helium Ltd (AIM:QHE) has mapped out five new drilling targets in Colorado after strong helium and oil results. It's now planning a bigger stimulation programm
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) jumped 6% after a new study showed its Parsortix system can spot cancer drug targets in blood samples. It even caught targets that rival tests would've missed completely. Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has dosed its first US patient with a reworked version of its cancer drug AO-252. The new capsule fixes an absorption problem and no safety issues have shown up yet. Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) got fast-tracked examination from the US patent office for its longevity gene variant. It's also had a second patent publishe
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.